Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | FBP1 | P09467 | 3/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18109191 | 0.81 | CA2 (0.44) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL1647472 | 0.74 | ALDH1A1 (0.44) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL918848 | 0.74 | AKR1C1 (0.54) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL389392 | 0.74 | AKR1C1 (0.54) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL368124 | 0.74 | AKR1C1 (0.54) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL19953569 | 0.71 | MAOB (0.53) | ESR1ALDH1A1TSHRTRPA1CYP3A4 | |
| SCHEMBL19668043 | 0.70 | CA1 (0.52) | ALDH1A1TSHRTRPA1CYP3A4 | |
| SCHEMBL29253620 | 0.69 | ALDH1A1 (0.50) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL131223 | 0.69 | MAOB (0.53) | ESR1ALDH1A1TSHRAKR1C3AKR1C1 | |
| SCHEMBL2505599 | 0.69 | TSHR (0.41) | ESR1ALDH1A1TSHRAKR1C3TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | claimed |
| EP-4427758-A1 | NEW SYNERGISTIC ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIBACTERIAL ASSOCIATION | NOOS S.r.l. (IT) | 2024-09-11 | — | — | EP | claimed |
| US-20230141224-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC | 2023-05-11 | — | — | US | claimed |
| EP-4142751-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | Figene, LLC (US) | 2023-03-08 | — | — | EP | claimed |
| WO-2021202032-A1 | FIBROBLAST MEDIATED EXPANSION AND AUGMENTATION OF IMMUNE REGULATORY CELLS FOR TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) | FIGENE, LLC (US) | 2021-10-07 | — | — | WO | claimed |
| EP-4678169-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFECTIONS WITH RSV | Szekeres, Thomas (AT) | 2026-01-14 | — | — | EP | disclosed |
| EP-4516298-A1 | STILBENE COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF INFECTIONS WITH CYTOMEGALOVIRUS (CMV) | Szekeres, Thomas (AT) | 2025-03-05 | — | — | EP | disclosed |
| EP-4313010-B1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | SZEKERES THOMAS (AT) | 2025-02-19 | — | — | EP | disclosed |
| WO-2024238399-A1 | METHODS OF MANUFACTURING ADENO-ASSOCIATED VIRAL VECTORS | SIREN BIOTECHNOLOGY, INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| EP-4427758-A1 | NEW SYNERGISTIC ANTI-INFLAMMATORY, ANTIOXIDANT AND ANTIBACTERIAL ASSOCIATION | NOOS S.r.l. (IT) | 2024-09-11 | — | — | EP | disclosed |
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | SZEKERES THOMAS (AT) | 2024-05-23 | — | — | US | disclosed |
| EP-4313010-A1 | COMPOUNDS FOR USE IN THE TREATMENT AND PREVENTION OF COVID- 19 | Szekeres, Thomas (AT) | 2024-02-07 | — | — | EP | disclosed |
| WO-2012017451-A1 | A BIO-STABILIZED RESVERATROL FORMULATION | KHANDELWAL SANJEEV (IN) | 2012-02-09 | — | — | WO | disclosed |
| EP-1654210-B1 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2008-07-30 | — | — | EP | disclosed |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | SZEKERES THOMAS | 2007-08-16 | — | — | US | disclosed |
| WO-2007002973-A2 | USE OF STILBENE DERIVATIVES FOR THE PRODUCTION OF MEDICAMENTS FOR THE TREATMENT OF SOLID TUMOURS | MEDIZINISCHE UNIVERSITÄT WIEN (AT) | 2007-01-11 | — | — | WO | disclosed |
| EP-1654210-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | Szekeres, Thomas (AT) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005102298-A1 | MEDICAL SUBSTANCE MIXTURES CONTAINING RESVERATROL OR RESVERATROL-DERIVATIVES, IN ADDITION TO THE USE THEREOF IN THE PRODUCTION OF MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005016860-A2 | STILBENE DERIVATIVES AND THEIR USE IN MEDICAMENTS | SZEKERES THOMAS (AT) | 2005-02-24 | — | — | WO | disclosed |
| EP-1068864-A1 | Use of at least a hydroxystilbene as a glycation inhibitor | L'OREAL (FR) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166587-A1 | SARS-CoV-2 inhibitors - artificial compounds | ACE2, ACE, FURIN | ESR1 833/4885ALDH1A1 2822/4885TSHR 3012/4885 |
| US-20070191627-A1 | Stilbene derivatives and their use in medicaments | PTGS2, PTGS1, PTGER2 | ESR1 330/4885ALDH1A1 333/4885TSHR 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.